James Howard Tonsgard to Neurilemmoma
This is a "connection" page, showing publications James Howard Tonsgard has written about Neurilemmoma.
Connection Strength
0.568
-
Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104. J Neurooncol. 2025 Jul; 173(3):751-757.
Score: 0.225
-
Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials. Neurology. 2021 08 17; 97(7 Suppl 1):S50-S63.
Score: 0.172
-
Expression profiling of 519 kinase genes in matched malignant peripheral nerve sheath tumor/plexiform neurofibroma samples is discriminatory and identifies mitotic regulators BUB1B, PBK and NEK2 as overexpressed with transformation. Mod Pathol. 2013 Jul; 26(7):930-43.
Score: 0.096
-
Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma. Neuro Oncol. 2023 08 03; 25(8):1498-1506.
Score: 0.050
-
Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials. Neurology. 2013 Nov 19; 81(21 Suppl 1):S6-14.
Score: 0.025